Medications

What is the SELECT Trial? Understanding GLP-1 Cardiovascular Research

Understanding the SELECT Trial and Its Impact on Heart Health

If you've been following news about GLP-1 medications like semaglutide, you might have heard about a groundbreaking study called the SELECT trial. This research changed how we understand these medications—proving they offer benefits that extend far beyond weight loss.

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) is one of the largest cardiovascular outcome trials ever conducted for a weight management medication. Its findings have significant implications for millions of people living with obesity and heart disease.

Let's break down what this important study discovered and what it means for your health.

What Was the SELECT Trial Studying?

The SELECT trial was designed to answer a critical question: Can semaglutide reduce the risk of major cardiovascular events in people with overweight or obesity who already have established heart disease?

This multinational study enrolled over 17,600 participants across 41 countries. All participants were adults aged 45 or older with a BMI of 27 or higher and pre-existing cardiovascular disease—but importantly, they did not have diabetes.

Researchers divided participants into two groups: one receiving weekly injections of semaglutide 2.4 mg (the same dose used for weight management), and another receiving a placebo. The study followed participants for an average of 40 months, tracking cardiovascular events like heart attacks, strokes, and cardiovascular death.

This was significant because previous GLP-1 research had primarily focused on people with type 2 diabetes. The SELECT trial specifically examined whether the cardiovascular benefits extended to people without diabetes.

Key Findings From the SELECT Trial

The results, published in November 2023 in the New England Journal of Medicine, were remarkable.

Participants taking semaglutide experienced a 20% reduction in major adverse cardiovascular events (MACE) compared to those taking placebo. This included significant reductions in:

The benefits appeared early and were sustained throughout the study period. Notably, these cardiovascular improvements occurred alongside an average weight loss of 9.4% of body weight.

Perhaps most importantly, the cardiovascular benefits seemed to extend beyond what could be explained by weight loss alone. Researchers observed that the reduction in heart attacks and strokes began appearing before significant weight loss occurred, suggesting semaglutide may have direct protective effects on the cardiovascular system.

How Does Semaglutide Protect the Heart?

While weight loss certainly contributes to improved heart health, scientists believe semaglutide offers cardiovascular protection through multiple pathways.

GLP-1 medications like semaglutide appear to reduce inflammation throughout the body, including in blood vessels. Chronic inflammation plays a major role in developing atherosclerosis—the buildup of plaque in arteries that leads to heart attacks and strokes.

These medications also improve several cardiovascular risk factors beyond weight, including blood pressure, blood sugar levels, and lipid profiles. Additionally, some research suggests GLP-1 receptors exist in heart tissue and blood vessels, meaning semaglutide may have direct effects on these organs.

The SELECT trial's findings have prompted researchers to explore GLP-1 medications for other cardiovascular and inflammatory conditions. You can learn more about ongoing GLP-1 research on our blog at ozarihealth.com/blog.

What the SELECT Trial Means for Patients

The SELECT trial's results represent a paradigm shift in how we view obesity treatment. For decades, excess weight was often dismissed as a cosmetic concern or character flaw. This research reinforces that obesity is a chronic disease with serious health consequences—and that treating it can literally save lives.

For people living with both obesity and heart disease, these findings are particularly meaningful. The study suggests that semaglutide isn't just about fitting into smaller clothes—it's about reducing your risk of life-threatening cardiovascular events.

The trial also validates what many healthcare providers have observed in clinical practice: GLP-1 medications offer wide-ranging metabolic and cardiovascular benefits that improve overall health.

It's worth noting that while the SELECT trial used brand-name semaglutide, compounded versions contain the same active ingredient and work through the same mechanisms in your body.

Frequently Asked Questions

Who was included in the SELECT trial?

The SELECT trial enrolled adults aged 45 or older with a BMI of 27 or higher and established cardiovascular disease (previous heart attack, stroke, or peripheral artery disease). Importantly, participants did not have diabetes. This made the study unique because it focused specifically on cardiovascular outcomes in people with obesity but without diabetes.

Does semaglutide prevent heart attacks and strokes in everyone?

The SELECT trial specifically studied people with pre-existing cardiovascular disease. While the results are promising, we don't yet know if semaglutide provides the same degree of cardiovascular protection in people without established heart disease. However, improving risk factors like weight, blood pressure, and inflammation likely benefits heart health across populations. Always discuss your individual cardiovascular risk with your healthcare provider.

How long does it take for cardiovascular benefits to appear?

In the SELECT trial, researchers observed cardiovascular benefits beginning relatively early in treatment—within the first year. Interestingly, some benefits appeared before participants had lost significant weight, suggesting semaglutide may offer cardiovascular protection through mechanisms beyond weight loss alone. The benefits continued throughout the study's duration of over three years.

Key Takeaways

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, prescribed by licensed providers and shipped to your door. Learn more at ozarihealth.com.

Reviewed by the Ozari Clinical Content Team (OCCT) — health writers and wellness professionals specializing in GLP-1 therapy and metabolic health. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.